Citadel Advisors’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $30.1M | Sell |
924,600
-511,000
| -36% | -$16.4M | ﹤0.01% | 1860 |
|
|
2025
Q4 | $50.5M | Buy |
1,435,600
+167,800
| +13% | +$5.95M | 0.01% | 1403 |
|
|
2025
Q3 | $33.3M | Buy |
1,267,800
+170,500
| +16% | +$5.09M | 0.01% | 1764 |
|
|
2025
Q2 | $29.1M | Sell |
1,097,300
-222,300
| -17% | -$5.85M | 0.01% | 1712 |
|
|
2025
Q1 | $31.9M | Buy |
1,319,600
+689,100
| +109% | +$21.8M | 0.01% | 1531 |
|
|
2024
Q4 | $25.4M | Sell |
630,500
-435,000
| -41% | -$24.8M | ﹤0.01% | 1909 |
|
|
2024
Q3 | $67.5M | Buy |
1,065,500
+92,100
| +9% | +$5.4M | 0.01% | 972 |
|
|
2024
Q2 | $51.6M | Sell |
973,400
-326,000
| -25% | -$21.4M | 0.01% | 1123 |
|
|
2024
Q1 | $107M | Buy |
1,299,400
+1,022,600
| +369% | +$45.5M | 0.02% | 659 |
|
|
2023
Q4 | $5.15M | Sell |
276,800
-79,500
| -22% | -$1.04M | ﹤0.01% | 3744 |
|
|
2023
Q3 | $3.94M | Sell |
356,300
-250,200
| -41% | -$3.58M | ﹤0.01% | 4036 |
|
|
2023
Q2 | $9.83M | Buy |
606,500
+19,100
| +3% | +$400K | ﹤0.01% | 2697 |
|
|
2023
Q1 | $9.78M | Buy |
587,400
+125,500
| +27% | +$1.3M | ﹤0.01% | 2846 |
|
|
2022
Q4 | $4.34M | Buy |
461,900
+392,100
| +562% | +$1.75M | ﹤0.01% | 4092 |
|
|
2022
Q3 | $190K | Sell |
69,800
-1,600
| -2% | -$5.24K | ﹤0.01% | 10454 |
|
|
2022
Q2 | $206K | Sell |
71,400
-13,000
| -15% | -$32.2K | ﹤0.01% | 10642 |
|
|
2022
Q1 | $253K | Buy |
84,400
+37,800
| +81% | +$136K | ﹤0.01% | 10969 |
|
|
2021
Q4 | $214K | Sell |
46,600
-72,900
| -61% | -$409K | ﹤0.01% | 11712 |
|
|
2021
Q3 | $750K | Buy |
119,500
+14,100
| +13% | +$87.1K | ﹤0.01% | 8873 |
|
|
2021
Q2 | $631K | Sell |
105,400
-24,600
| -19% | -$146K | ﹤0.01% | 9494 |
|
|
2021
Q1 | $822K | Sell |
130,000
-59,800
| -32% | -$421K | ﹤0.01% | 8588 |
|
|
2020
Q4 | $1.07M | Sell |
189,800
-31,600
| -14% | -$191K | ﹤0.01% | 6672 |
|
|
2020
Q3 | $1.29M | Buy |
221,400
+6,600
| +3% | +$45.4K | ﹤0.01% | 5564 |
|
|
2020
Q2 | $1.55M | Sell |
214,800
-129,200
| -38% | -$858K | ﹤0.01% | 5018 |
|
|
2020
Q1 | $1.61M | Sell |
344,000
-100,800
| -23% | -$620K | ﹤0.01% | 4498 |
|
|
2019
Q4 | $3.57M | Buy |
444,800
+38,600
| +10% | +$281K | ﹤0.01% | 3547 |
|
|
2019
Q3 | $2.79M | Sell |
406,200
-35,500
| -8% | -$264K | ﹤0.01% | 3960 |
|
|
2019
Q2 | $3.67M | Buy |
441,700
+33,300
| +8% | +$285K | ﹤0.01% | 3543 |
|
|
2019
Q1 | $4.06M | Buy |
408,400
+110,400
| +37% | +$924K | ﹤0.01% | 3288 |
|
|
2018
Q4 | $2.28M | Buy |
298,000
+20,700
| +7% | +$247K | ﹤0.01% | 3941 |
|
|
2018
Q3 | $4.83M | Buy |
277,300
+186,400
| +205% | +$2.22M | ﹤0.01% | 3055 |
|
|
2018
Q2 | $863K | Buy |
+90,900
| New | +$605K | ﹤0.01% | 5473 |
|
Other funds holding VKTX
VCM
VPM
Citadel Advisors's VKTX Position: Q1 2026 in Review
Citadel Advisors reduced its Viking Therapeutics (VKTX) stake by 27% in Q1 2026, selling an estimated $15.1M and leaving 1,262,221 shares worth $41.1M. The position accounts for 0.01% of the portfolio, ranked #1545.
Citadel Advisors first reported a position in VKTX in Q1 2016 and has held it in 33 quarters since. The position peaked at $93.2M in Q3 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- Citadel Advisors held 1,262,221 shares of Viking Therapeutics worth $41.1M as of Q1 2026.
- Citadel Advisors sold 470,200 Viking Therapeutics shares in Q1 2026, an estimated $15.1M.
- Viking Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1545 holding.
- Citadel Advisors first reported a position in Viking Therapeutics in Q1 2016 and has held it in 33 quarters since.
- Citadel Advisors's Viking Therapeutics position peaked at $93.2M in Q3 2024.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.